Current evidence suggests that hyperactivity of the sympathetic nervous system, and endothelial dysfunction are important factors in the development and maintenance of hypertension. Under normal conditions the endothelial mediator nitric oxide (NO) negatively modulates the activity of the norepinephrine portion of sympathetic neurotransmission, thereby placing a "brake" on the vasoconstrictor ability of this transmitter. This property of NO is diminished in the isolated perfused mesenteric arterial bed taken from the spontaneously hypertensive rat (SHR), resulting in greater nerve-stimulated norepinephrine and lower neuropeptide Y (NPY) overflow from this mesenteric preparation compared to that of the normotensive Wistar Kyoto (WKY) rat.
INTRODUCTION
In addition to the sympathetic nervous system (SNS), the endothelium of the vasculature is also an extremely important component of vascular control. Among the many mediators released by the endothelium, one of the most important is the powerful vasodilator nitric oxide (NO). In addition to its direct effects on the vasculature, NO also modulates sympathetic neurotransmission (4, 8, 18, 51, 58) . We have shown that one mechanism by which NO modulates sympathetic neurotransmission is by deactivating a portion of the norepinephrine in the neuroeffector junction (27), thus placing a "brake" on both the post and pre-junctional activity of norepinephrine. An indirect consequence of this property of NO is a limit on the negative regulation of sympathetic cotransmission by norepinephrine. Indeed we have shown that NPY release from sympathetic nerves is greater as a result of the deactivation of norepinephrine by NO (26, 27) . Taken together these findings demonstrate the importance of NO as a physiological modulator of the SNS.
The events that lead to the development of hypertension are still unclear but increased activity of the SNS and development of endothelial dysfunction have both been implicated. There is considerable evidence for hyperactivity of the SNS in contributing to the initiation and maintenance of hypertension in a significant proportion of the hypertensive population (1, 12-14, 17, 40) as well as in various experimental models such as the Spontaneously Hypertensive Rat (SHR) (21, 25, 46, 55). However, the precise causal mechanisms leading to increased sympathetic activity are still poorly understood.
Increased oxidative stress, evident in hypertension (3, 10, 20, 62) , may be a factor in hyperactivity of the SNS since oxidative stress leads to the loss of the bioavailability of NO as a result of a reaction with superoxide anion (O 2 -) (31, 36, 49).
This loss of NO would lead to an increase in the amount of norepinephrine within the neuroeffector junction and may explain our previous observations of compromised NO modulation of sympathetic neurotransmission in the young (10-12 week old) SHR (26).
In this study we investigated the involvement of oxidative stress in changes observed in NO mediated modulation of sympathetic neurotransmission in the SHR. As mentioned above we have demonstrated that by deactivating norepinephrine, endogenous NO modulates sympathetic neurotransmission at the vascular neuroeffector junction of the rat mesenteric arterial bed (27). We further showed that this modulation is compromised in mesenteric preparations taken from 10-12 week old SHR (26) contributing to the increased nerve-stimulated overflow of norepinephrine and concomitant decrease in NPY overflow, observed in SHR compared to normotensive Wistar Kyoto (WKY) controls. In order to examine the possible involvement of oxidative stress in the changes observed in the modulation of sympathetic neurotransmission in the SHR, we carried out experiments utilizing the antioxidant n-acetylcysteine. Our rationale was that if O 2 -has increased in the vascular smooth muscle of the SHR as has been reported (19, 44, 60) then the addition of an antioxidant should protect NO from deactivation by O 2 -and this should be reflected in a transition towards normal levels in the nerve stimulated induced overflow of sympathetic neurotransmitters. Our results confirm that the hyperactivity of the SNS in hypertension may be driven, in part, by oxidative stress.
MATERIALS AND METHODS

Materials
.
Krebs' buffer salts were all purchased from Sigma (St. Louis, MO). BIBO 3304 was a kind gift from from Boehringer Ingelheim GmbH (Biberach, Germany). The NPY EIA kit was purchased from Peninsula Laboratories (San Carlos, CA).
Animals.
All procedures were carried out in accordance with National The remaining intestine was then separated from the vascular bed along the intestinal wall. The dissected vascular bed was placed in an organ bath maintained at 37 °C and perfused and superfused with a modified Krebs' buffer by a Gilson minipulse pump at a rate of 2 ml/min and 0.5 ml/min respectively. The Krebs buffer was composed of (in 
RESULTS
All our experiments were carried out on mesenteric preparations taken from 10-12 week old SHR and compared to age-matched normotensive WKY genetic controls.
This age-group represents a young hypertensive animal, i.e. one in which hypertension is still developing. SHR have been extensively studied and it is well established that these animals develop hypertension as they age. From 4-6 weeks the blood pressure of the SHR is, for the most part, comparable to the WKY although some reports indicate that there are already significant differences between the two strains (28, 32, 39, 48, 56). The blood pressure of SHR then begins to rise sharply until the rats are 10-12
weeks old. The increase in blood pressure of SHR then slows and around 18-20 weeks has stabilized (59). The SHR rats used in our experiments exhibited mean arterial pressures of 130 ± 4 mmHg, significantly greater than 88 ± 2 mmHg for WKY (n=6;
P<0.005).
Nerve stimulated perfusion pressure responses are greater in mesenteric beds from SHR than WKY controls.
The mean basal perfusion pressures of isolated perfused mesenteric arterial beds taken from WKY and SHR were 22.4 ± 4.7 and 18.9 ± 3 mmHg respectively.
Periarterial nerve stimulation at 12Hz increased the perfusion pressure to 71.6 ± 8.9
and 131 ± 16 mmHg for WKY and SHR respectively. Figure 1 depicts these changes as % increase over basal for both rat strains with the increase for SHR significantly higher than that for WKY (n=8; P<0.01 vs. WKY).
Nerve stimulated overflow of norepinephrine from the mesenteric preparation is greater in SHR than WKY, but NPY overflow is greater in WKY than SHR.
In terms of neurotransmitter overflow Figure 2 depicts nerve stimulated norepinephrine and NPY overflow for WKY and SHR preparations. The increase in norepinephrine was significantly higher from SHR preparations (163 ± 29 %) compared to WKY (79.62 ± 20%; Fig. 2A 
N-acetylcysteine reduces the nerve stimulated mesenteric overflow of norepinephrine and increases NPY overflow from SHR preparations by increasing the bioavailability of NO.
In the presence of n-acetylcysteine (5 mM) nerve stimulated norepinephrine overflow from the SHR mesenteric bed significantly decreased from 163 ± 29 to 30.6 ± 16.3 % over basal ( Fig. 3A; n=8; P<0.01 vs. control). In contrast, nerve stimulated NPY overflow from the mesenteric bed of the SHR significantly increased in the presence of n-acetylcysteine from 93 ± 16 to 362 ± 87 % over basal ( Fig. 3B; n=8 ; P<0.01 vs control). The overflow of both norepinephrine and NPY from the WKY mesenteric bed was not significantly altered in the presence of n-acetylcysteine (Fig 4; n=8) .
Since our hypothesis is that oxidative stress reduces the bioavailability of NO in the SHR thus leading to increased norepinephrine overflow and, as a result, decreased NPY overflow when compared to WKY, it appears likely that n-acetylcysteine is reversing this pattern of neurotransmitter overflow by protecting NO. To test this we included the NOS inhibitor L-NAME along with n-acetylcysteine in the perfusion buffer of preparations taken from SHR. Including L-NAME (30 µM) prevented the effect of n-acetylcysteine (5 mM) on nerve-stimulated norepinephrine (115 ± 14.7 % over basal;
P<0.01 vs. n-acetylcysteine alone) and NPY overflow (121 ± 44% over basal; P<0.05 vs. n-acetylcysteine alone), confirming that the antioxidant was having its effect by preserving NO (Fig. 3; n=5) . WKY preparations were not treated with L-NAME and n-acetylcysteine, as they showed no change in neurotransmitter overflow in the presence of n-acetylcysteine alone.
Nerve stimulated perfusion pressure responses in preparations from the SHR were unaffected by the presence of n-acetylcysteine alone or in conjunction with L-NAME (Fig 5A; n=8) , n-acetylcysteine).
Oxidative Stress is increased in SHR.
Aortic tissue from the animals used in the above experiments was harvested in order to assess the general level of oxidative stress via levels of lipid hydroperoxide (LPO) in the vasculature. LPO levels in aortic tissue taken from SHR were significantly higher than that for WKY (84 ± 18 vs. 13.8 ± 1.5 nmol/mg tissue respectively; n=6;
P<0.005 vs. WKY).
DISCUSSION
These results confirm our previous observations on the differences that exist in sympathetic neurotransmission in mesenteric preparations taken from young (10-12 week old) SHR and their normotensive age-matched WKY controls (26). Specifically they demonstrate that whereas nerve-stimulated norepinephrine overflow is greater from the mesenteric arterial bed of 10-12 week SHR than WKY, nerve-stimulated NPY overflow is less. Prejunctional inhibitory activity by sympathetic co-transmitters on sympathetic neurotransmission is well established (30, 43, 54, 55). Therefore it is likely that elevated norepinephrine overflow in the SHR is negatively feeding back through prejunctional α 2 receptors and reducing NPY overflow.
The present study was designed to investigate the role of increased oxidative stress in the increase in norepinephrine overflow in mesenteric preparations taken from the 10-12 week old SHR. We have previously shown that NO modulates norepinephrine activity under physiological conditions (27) and that this modulation is compromised in the SHR (26). NO bioavailability is known to be adversely affected by increased oxidative stress (31, 36, 49), and increased oxidative stress has been shown to occur in hypertension (3, 10, 20, 62) . For that reason we focused this study on the role played by increased oxidative stress in the alterations in sympathetic neurotransmission in the SHR, with specific attention to NO bioavailability. Our results confirm that oxidative stress is indeed involved in the changes that occur in sympathetic neurotransmission in hypertension. Specifically we show that the antioxidant n-acetylcysteine reduces the nerve-stimulated overflow of norepinephrine while concomitantly increasing the nervestimulated overflow of NPY from the mesenteric arterial beds of the SHR. Furthermore these changes were prevented by the NOS inhibitor L-NAME, demonstrating that the effects of n-acetylcysteine on neurotransmitter overflow, are indeed due to protection of the bioavailability of NO. In contrast we show that neurotransmitter overflow in the normotensive age-matched WKY is not affected by n-acetylcysteine which is unsurprising given that NO induced modulation of sympathetic neurotransmission is likely already optimal in normotensive rats (26, 27) and oxidative stress should not be a factor. Indeed, lipid hydroperoxide analysis of aortic tissue taken from both sets of rats show that SHR tissue has much greater levels of this lipid peroxidation marker than that of WKY.
Perfusion pressure responses in mesenteric preparations taken from the SHR, already significantly higher than their WKY normotensive controls, showed no net change in the presence of n-acetylcysteine alone, or in combination with L-NAME. This was, on first analysis, somewhat surprising given the profound changes in neurotransmitter overflow. However, in the presence of n-acetylcysteine, nervestimulated norepinephrine overflow decreases and, at the same time, nerve-stimulated NPY overflow increases, thus it is probable that the NPY compensates for the loss of norepinephrine as far as perfusion pressure responses are concerned. Our experiments including the Y 1 antagonist BIBO 3304 confirm that NPY is indeed responsible for preserving the elevation in perfusion pressure responses. Similarly, the presence of both L-NAME and n-acetylcysteine in combination causes nerve-stimulated norepinephrine overflow to increase while NPY overflow decreases, again resulting in no net effect on perfusion pressure responses. This again is likely a result of compensation by one transmitter for another. In contrast perfusion pressure responses in WKY preparations were slightly, but significantly reduced in the presence of nacetylcysteine despite no significant changes in neurotransmitter overflow. It is known that vascular NADPH oxidase, the major source of vascular O 2 -production (6, 11), has some constitutive activity, and the O 2 -produced by its activity is thought to play a physiological role in limiting the activity of the endothelial derived vasodilator NO (7).
Therefore the decrease in perfusion pressure responses in the WKY preparations is likely due to heightened NO availability at the vascular smooth muscle causing physiological antagonism to sympathetic vasoconstrictors. Although this must also be happening to some extent in the SHR preparations treated with n-acetylcysteine, it is likely masked by the overwhelming vasoconstrictor properties of the neurotransmitters.
Indeed, perfusion pressure responses in the SHR preparations treated with both L-NAME and n-acetylcysteine although not significantly different from SHR control, do show a moderate increase in perfusion pressure, possibly suggestive of a loss of this direct vasodilatory effect of NO as we demonstrated previously for L-NAME alone (26). and it has been shown that treating such animals with ACE inhibitors or AT-1 receptor
antagonists not only reverses the hypertensive response but also reduces oxidative stress markers (16, 38, 53, 61).
Thus it could be argued that the RAS deals a triple blow to the regulation of normal vascular tone in that it is a direct vasoconstrictor in its own right, it increases sympathetic neurotransmission and it decreases the availability of NO as a result of increasing oxidative stress. All these factors undoubtedly factor into the success of ACE inhibitors and AT-1 receptor antagonists as anti-hypertensive therapies. The loss in NO function as a result of the actions of O 2 -is further compounded by the fact that NO not only acts as a direct vasodilator, it also modulates sympathetic neurotransmission.
Given this latter point, it is possible that part of the positive modulatory effect of Ang II on sympathetic neurotransmission is due to the stimulation of oxidative stress.
Perhaps the most convincing evidence for the importance of oxidative stress in the pathogenesis of hypertension comes from studies showing that antioxidant treatment improves endothelial function and lowers blood pressure in experimental models of hypertension (5, 9, 15, 23, 41, 42, 47 is decreased in the presence of NAC (5 mM; n=8). * P<0.05 compared to control.
